Catabasis Pharmaceuticals (NASDAQ:CATB) Earns Daily News Sentiment Score of 0.17

News articles about Catabasis Pharmaceuticals (NASDAQ:CATB) have trended somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Catabasis Pharmaceuticals earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 44.9856350552491 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of research analysts recently weighed in on CATB shares. Zacks Investment Research lowered Catabasis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, October 16th. Wedbush restated an “outperform” rating and issued a $4.00 price target on shares of Catabasis Pharmaceuticals in a research note on Friday, December 15th. Finally, Citigroup upgraded Catabasis Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $3.00 price target for the company in a research note on Monday, November 20th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Catabasis Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $4.82.

Shares of Catabasis Pharmaceuticals (NASDAQ:CATB) opened at $1.34 on Tuesday. Catabasis Pharmaceuticals has a 1 year low of $1.09 and a 1 year high of $3.78. The firm has a market capitalization of $30.70 and a price-to-earnings ratio of -0.89.

Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.02. The business had revenue of $0.25 million for the quarter. equities analysts expect that Catabasis Pharmaceuticals will post -1.38 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Catabasis Pharmaceuticals (NASDAQ:CATB) Earns Daily News Sentiment Score of 0.17” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/06/catabasis-pharmaceuticals-catb-given-daily-news-sentiment-score-of-0-17.html.

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Insider Buying and Selling by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply